ADMA Biologics (NASDAQ:ADMA – Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect ADMA Biologics to post earnings of $0.16 per share and revenue of $125.3440 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.11 EPS. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
ADMA Biologics Price Performance
ADMA opened at $8.79 on Wednesday. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $8.48 and a two-hundred day simple moving average of $11.75. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 12.93 and a beta of 0.73. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46.
More ADMA Biologics News
- Positive Sentiment: Earnings date provides a potential catalyst: ADMA Biologics will release its second-quarter 2026 financial results on August 5 after the market closes and host a conference call at 4:30 p.m. ET. Investors will be looking for updates on revenue, ASCENIV demand, inventory levels, and the company’s outlook. ADMA Biologics to Report Second Quarter 2026 Financial Results
- Neutral Sentiment: Investors await clarification from management: The earnings release and conference call may offer the first significant opportunity for management to address the allegations surrounding revenue recognition, distributor inventory, and business practices. The outcome could increase volatility in either direction.
- Negative Sentiment: Multiple law firms are promoting a securities-fraud class action: Several firms, including Bleichmar Fonti & Auld, Kahn Swick & Foti, Pomerantz, Hagens Berman, Rosen, and others, announced notices tied to a lawsuit against ADMA and certain executives. The announcements cite alleged misrepresentations concerning the company’s financial condition, internal controls, revenue recognition, inventory distribution, and business practices. ADMA investors have until August 10, 2026, to seek appointment as lead plaintiff. The allegations have not been proven in court. ADMA Court Deadline Securities Fraud Class Action
- Negative Sentiment: Claims focus on potentially inflated sales: One investor notice alleges that ADMA shipped unwanted ASCENIV inventory to distributors, creating artificial demand, while other notices reference alleged channel stuffing and omitted related-party sales. These claims raise risks of revenue reversals, regulatory scrutiny, litigation costs, and reputational damage if substantiated. ADMA Investor Class Action Allegations
Insiders Place Their Bets
In other ADMA Biologics news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 3.90% of the company’s stock.
Institutional Trading of ADMA Biologics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC purchased a new position in ADMA Biologics in the 4th quarter worth approximately $29,000. iSAM Funds UK Ltd purchased a new stake in ADMA Biologics during the 3rd quarter valued at approximately $34,000. EverSource Wealth Advisors LLC grew its holdings in ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $72,000. Institutional investors own 75.68% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on ADMA. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Mizuho decreased their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Canaccord Genuity Group cut their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.
Get Our Latest Stock Analysis on ADMA Biologics
About ADMA Biologics
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Stories
- Five stocks we like better than ADMA Biologics
- Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile
- NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
